MacroGenics Reports Q4 Earnings

Biopharmaceutical company exceeds Wall Street expectations

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

MacroGenics Inc., a biopharmaceutical company based in Rockville, Maryland, reported a loss of $14.2 million in its fourth quarter. However, the company's results exceeded Wall Street expectations, with revenue of $41.2 million in the period, surpassing Street forecasts.

Why it matters

MacroGenics is a prominent biopharmaceutical company, and its quarterly earnings reports are closely watched by investors and industry analysts to gauge the company's financial health and performance. The company's ability to exceed expectations in both earnings and revenue is a positive sign for its business.

The details

In the fourth quarter, MacroGenics reported a loss of $14.2 million, or 22 cents per share. This was better than the average estimate of four analysts surveyed by Zacks Investment Research, who had expected a loss of 42 cents per share. The company also posted revenue of $41.2 million in the period, which was higher than the $24.1 million expected by three analysts surveyed by Zacks.

  • MacroGenics reported its Q4 earnings on Monday, March 9, 2026.

The players

MacroGenics Inc.

A biopharmaceutical company based in Rockville, Maryland, that develops and commercializes monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders, and infectious diseases.

Got photos? Submit your photos here. ›

The takeaway

MacroGenics' ability to exceed Wall Street's expectations in its Q4 earnings report is a positive sign for the company's financial performance and business outlook. The strong revenue and narrower-than-expected loss suggest the company is making progress in its drug development and commercialization efforts.